verified SJR 1,187 · Q1 • database Scopus / SJR & Web of Science indexed

United States · Elsevier Inc.

workspace_premium Q1 — Oncology lock_open Open Access

Clinical Colorectal Cancer

Clinical Colorectal Cancer is a journal indexed in SJR in Oncology and Gastroenterology with an H index of 67. It has an SJR impact factor of 1,187 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,187.

ISSN: 1533-0028

Publisher: Elsevier Inc.

Category: Oncology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,187 Q1

H-index 67

Acceptance rate pie_chart

30% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

NPD Open Access

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,187

H-index

Docs (year)

Docs 3y

209

Total refs

1874

Cites 3y

614

Citable 3y

197

Cites/Doc 2y

2.95

Ref/Doc

41.64

Immediate OA

—

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Commentary on "Thymidylate Synthase Gene Expression in Primary Colorectal Cancer and Metastatic Sites"

Upper Gastrointestinal Malignancies: A New Era in Clinical Colorectal Cancer

First-Line Capecitabine is as Effective as 5-Fluorouracil/Leucovorin in Treating Advanced Colorectal Cancer

Factors Predicting Adherence to a Tailored-Dose Adjuvant Treatment on the Basis of Geriatric Assessment in Elderly People With Colorectal Cancer: A Prospective Study

Exploratory Study of Hepatic Arterial Infusion Oxaliplatin With Systemic 5-Fluorouracil/Bevacizumab in Patients With Refractory Solid Tumor and Extensive Liver Metastases

Equal Opportunity for the Elderly

Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (=75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study

Effect of Delay in Adjuvant Oxaliplatin-Based Chemotherapy for Stage III Colon Cancer

Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer

Edrecolomab (Panorex¬Æ) as Adjuvant Therapy for Stage II Colon Cancer

Delayed Reversible Posterior Encephalopathy Syndrome Following Chemotherapy with Oxaliplatin

Cost-Effectiveness of Adjuvant Chemotherapy in the Treatment of Early-Stage Colon Cancer

SHOW MORE ARTICLES

Commentary on "Thymidylate Synthase Pharmacogenetics in Colorectal Cancer"

25th European Society for Medical Oncology Congress; Hamburg, Germany October 13-17, 2000

Commentary on "The Role of Adjuvant Therapy After Liver Resection for Colorectal Metastases"

Collision Tumor of the Large Bowel in the Context of Advanced Pregnancy and Ulcerative Colitis

Cetuximab Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: The LABEL Study

Cetuximab is Associated With Excessive Toxicity When Combined With Bevacizumab Plus mFOLFOX6 in Metastatic Colorectal Carcinoma

Case Report of Rhabdoid Colon Cancer and Review of Literature

Capecitabine Combinations in the Treatment of Advanced Colorectal Cancer

Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine

Body Surface Area-based Dosing of 5-Fluoruracil Results in Extensive Interindividual Variability in 5-Fluorouracil Exposure in Colorectal Cancer Patients on FOLFOX Regimens

An Overview of Adjuvant Systemic Chemotherapy for Colon Cancer

Adjuvant Chemotherapy for Elderly Patients With Colon Cancer: A Vanishing Paradigm?

FAQs

Clinical Colorectal Cancer has an SJR of 1,187 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is not available (NPD). Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Clinical Colorectal Cancer is 30%.

Clinical Colorectal Cancer

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Clinical Colorectal Cancer?

What is the APC / publication cost?

What is the acceptance rate?